Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17109724 | 0.85 | NOS3 (0.48) | ALDH1A1NPSR1L3MBTL1GAANOS3 | |
| SCHEMBL18924325 | 0.85 | KIF11 (0.37) | KIF11ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL19214824 | 0.85 | KIF11 (0.37) | KIF11ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL1908532 | 0.82 | POLB (0.46) | KIF11ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL21325537 | 0.81 | ALDH1A1 (0.37) | KIF11ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL21475711 | 0.80 | KIF11 (0.41) | KIF11ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL18160809 | 0.80 | KIF11 (0.34) | KIF11ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL18372376 | 0.80 | KIF11 (0.38) | KIF11ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL21923243 | 0.80 | KIF11 (0.39) | KIF11ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL8532984 | 0.80 | KIF11 (0.39) | KIF11ALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168424-A1 | THERMALLY STABLE ANTIBACTERIAL QUATERNARY AMMONIUM NANOPARTICLES | NOBIO LTD. (IL) | 2022-06-02 | — | — | US | disclosed |
| US-10968206-B2 | Cannabinergic nitrate esters and related analogs | NORTHEASTERN UNIVERSITY (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210032270-A1 | BIARYL DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
| US-20190225596-A1 | Cannabinergic Nitrate Esters And Related Analogs | NORTHEASTERN UNIVERSITY | 2019-07-25 | — | — | US | disclosed |
| US-20190119268-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10189826-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9546165-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | KIF11 1494/4885ALDH1A1 2362/4885MEN1 1673/4885 |
| US-20210032270-A1 | BIARYL DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL APPLICATION THEREOF | PDCD1, PDCD1LG2, CD274 | KIF11 3129/4885ALDH1A1 281/4885MEN1 3519/4885 |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRAS, VHL, ESRRB | KIF11 4628/4885ALDH1A1 2384/4885MEN1 278/4885 |
| US-10968206-B2 | Cannabinergic nitrate esters and related analogs | CNR2, CNR1, CHRNB3 | KIF11 3172/4885ALDH1A1 1850/4885MEN1 3997/4885 |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | KIF11 4207/4885ALDH1A1 779/4885MEN1 3256/4885 |
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | KIF11 4303/4885ALDH1A1 2740/4885MEN1 3964/4885 |
| US-10189826-B2 | Heterocyclic compounds and methods of use | HRAS, VHL, ESRRB | KIF11 4628/4885ALDH1A1 2384/4885MEN1 278/4885 |
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | KIF11 1494/4885ALDH1A1 2362/4885MEN1 1673/4885 |
| US-20220168424-A1 | THERMALLY STABLE ANTIBACTERIAL QUATERNARY AMMONIUM NANOPARTICLES | ASNS, AAAS, AHSA1 | KIF11 2061/4885ALDH1A1 2777/4885MEN1 4056/4885 |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | PDK1, PDK2, PDK3 | KIF11 1494/4885ALDH1A1 2362/4885MEN1 1673/4885 |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | KIF11 1494/4885ALDH1A1 2362/4885MEN1 1673/4885 |
| US-20190225596-A1 | Cannabinergic Nitrate Esters And Related Analogs | CNR2, CNR1, CHRNB3 | KIF11 3172/4885ALDH1A1 1850/4885MEN1 3997/4885 |
| US-20190119268-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | KIF11 1494/4885ALDH1A1 2362/4885MEN1 1673/4885 |
| US-10183015-B2 | Heterocyclic compounds and methods of use | LIPC, CPT1A, FABP1 | KIF11 4207/4885ALDH1A1 779/4885MEN1 3256/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | KIF11 4628/4885ALDH1A1 2384/4885MEN1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.